Are we ready for patient-based effect sizes in clinical-trials research?
作者信息
Lehmann Harold P
出版信息
Med Decis Making. 2005 May-Jun;25(3):248-9. doi: 10.1177/0272989X05277579.
PMID:15951452
Abstract
摘要
相似文献
1
Are we ready for patient-based effect sizes in clinical-trials research?
Med Decis Making. 2005 May-Jun;25(3):248-9. doi: 10.1177/0272989X05277579.
2
Benefits, harms, and the design of clinical trials.
Med Decis Making. 2005 May-Jun;25(3):246-7. doi: 10.1177/0272989X05277287.
3
Optimal sample size determinations from an industry perspective based on the expected value of information.
Clin Trials. 2008;5(6):587-94. doi: 10.1177/1740774508098413.
4
A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
Stat Med. 2007 Nov 30;26(27):4976-88. doi: 10.1002/sim.2955.
5
Design and analysis issues for economic analysis alongside clinical trials.
Med Care. 2009 Jul;47(7 Suppl 1):S14-20. doi: 10.1097/MLR.0b013e3181a31971.
6
Economics in sample size determination for clinical trials.
QJM. 1995 Jul;88(7):517-21.
7
Procedures and methods of benefit assessments for medicines in Germany.
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
8
Making or losing money with participation in clinical trials: a decision analysis.
Onkologie. 2009 Jul;32(7):411-6. doi: 10.1159/000218362. Epub 2009 Jun 17.
9
10
[Conducting a cost-effectiveness trial in oncology: justification and method].
Bull Cancer. 2009 May;96(5):603-7. doi: 10.1684/bdc.2009.0867. Epub 2009 May 12.
Zotero 插件